Kidney Stones, Urolithiasis
Conditions
Keywords
Kidney stones, Urolithiasis, Extracorporeal shockwave lithotripsy, ESWL
Brief summary
Extracorporeal shockwave lithotripsy (ESWL) is a non-invasive standard treatment for kidney stones. This study will be conducted to evaluate the effectiveness of ESWL using MODULITH® SLX-F2 with stone tracking, compared to MODULITH® SLX-F2 without stone tracking, in adult patients with kidney stones, as measured by stone-free status.
Detailed description
The success of ESWL depends on multiple procedure- and patient-specific factors, one crucial factor being accurate stone targeting. Respiration induced kidney movement affects stone targeting as it results in the stone not being hit by the shock waves for up to 50% of the treatment time. To improve the accuracy of stone targeting and comminution, an additional tracking module has been incorporated into the state-of-the-art lithotripter MODULITH® SLX-F2. The device is CE marked including its tracking module. The scientific rationale for conducting this clinical investigation is based on the hypothesis that improved stone targeting through real-time tracking may lead to increased treatment efficacy and safety, as reflected by higher stone-free rates, reduced need for re-treatment, an increased quality of life, and lower adverse events rates.
Interventions
DEVICEESWL with kidney stone tracking (StorM-Track)
Starting ESWL on a low energy setting with stepwise ramping and at a frequency of 1.0 or 1.5 Hz. Up to a maximum of 3'500 shockwaves unless there is no stone visible in X-ray imaging. If fragments \> 4mm remain after the first ESWL treatment, a 2nd ESWL will be performed.
DEVICEStandard ESWL without stone tracking (StorM-Track disabled)
Same treatment protocol as for the intervention group. If fragments \> 4mm remain after the first ESWL treatment, a 2nd ESWL will be performed.
Sponsors
Storz Medical AG
Karolinska University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years 2. Single kidney stone (6 - 15 mm) in the target kidney 3. Stone density assessed by Hounsfield unit value (HU) ≤ 1,200 HU
Exclusion criteria
1. BMI \> 34.9 2. Target stone that cannot be localised 3. Presence of one or more additional stones \> 4 mm in the target kidney 4. Presence of one or more additional stones ≤ 4 mm located in the same calyx (upper, mid, or lower pole) or in the renal pelvis as the target stone 5. Stones with a density value of \> 1,200 HU 6. Skin to stone distance (SSD) \> 160 mm 7. The presence of obstructions, malformations or other factors preventing targeting or passing of the stone, including but not limited to the following: 1. Skeletal malformations and obesity, preventing targeting of the stone 2. Malignant tumour in the shockwave path 3. Arterial aneurysm or calcium deposits, or thrombosis in shockwave path 4. Brain, spinal column or air-filled tissue, especially the lungs, in the shockwave path 5. Obstruction distal to the stone (as this would hinder the passage of fragments through collecting system or ureter) 8. Any disease/medical condition, prior or concomitant medication/treatment/intervention, or implant that may affect this clinical investigation, and/or is contraindicated for the IMD, including but not limited to the following: 1. Severe nephrocalcinosis 2. Uncontrolled urinary tract infection 3. Coagulation disorders and bleeding diathesis, not compensated according to urological and hemostaseological guidelines 4. Anticoagulation or platelet inhibition therapy, not bridged according to urological and hemostaseological guidelines 5. Uncontrolled hypertension 6. Blood pressure \> 180/100 7. Active cardiac implants that are not authorized for use with ESWL 8. Pancreatitis 9. Ehlers-Danlos syndrome 10. Administration of contrast agents containing gases for ultrasound diagnostics less than 24 hours before treatment. 9. Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Stone-free rate (SFR) | 6±2 weeks post 1st treatment | Proportion of subjects who are stone free or present with clinically insignificant residual fragments (measuring ≤ 4 mm on CT) |
Countries
Sweden
Contacts
CONTACTMarkus Hübscher, PhD
Outcome results
None listed